What is the key scientific innovation described in the news regarding obesity treatment?

The key innovation is a peptide-drug conjugate that activates five distinct receptors—on the cell surface and in the nucleus—by combining a GLP-1-GIP peptide agonist with a ligand for another metabolic target, resulting in a quintuple-acting molecule with potent anti-obesity and anti-diabetic effects demonstrated in mice.

How does this new conjugate differ from existing multi-agonist drugs like tirzepatide and retatrutide?

Unlike tirzepatide (GLP-1 + GIP dual agonist) and retatrutide (GLP-1 + GIP + glucagon triple agonist), this new conjugate activates five receptors—including all three incretin receptors plus those for amylin and calcitonin—representing an expansion of polypharmacology beyond current clinical-stage candidates.

Not just GLP-1: Peptide-drug conjugate hits 5 obesity targets

Apr 30, 2026

A new peptide-drug conjugate activating five metabolic receptors demonstrated potent obesity and diabetes treatment in mice. Eli Lilly-funded researchers plan to present preclinical data on this quintuple agonist at an upcoming conference.

cen

2026-04-30

Not just GLP-1: Peptide-drug conjugate hits 5 obesity targets

2026-05-06

Eli Lilly Commits Additional $4.5 Billion Across Indiana Manufacturing Sites

2026-07-16

Asia Stocks to Track US Slide on Chipmaker Selloff: Markets Wrap

2026-08-23

Snoring, Subways and Stealth Ads: How Big Pharma Targets China's Waistline

Not just GLP-1: Peptide-drug conjugate hits 5 obesity targets

FAQ